Has Mark Rosing received payments from drug or device companies?

Yes. Drug and device makers reported $2,773 in general payments to Mark Rosing across 61 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Rosing did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Rosing come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Rosing

Obstetrics & Gynecology · Bronx, NYNPI 1639198476

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,675 of the $2,773 with a category attached, or 60.4%. 20 manufacturers reported payments, led by Lupin Inc. at 27.4% of the total.

$2,773in general payments, 2019–2025

Across 61 payments — averaging $45.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lupin Inc.$759
Fujirebio Diagnostics, Incorporated$350
Sumitomo Pharma America, Inc.$191
Astellas Pharma US Inc$184
Daiichi Sankyo Inc.$164
Coopersurgical, Inc.$164
plus $962 from 14 others

What the payments were for

Consulting fees$74827%
Food & beverage$1,67560%
Education$35013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lupin Inc.	2	$759
Fujirebio Diagnostics, Incorporated	1	$350
Sumitomo Pharma America, Inc.	5	$191
Astellas Pharma US Inc	5	$184
Daiichi Sankyo Inc.	7	$164
Coopersurgical, Inc.	7	$164
AbbVie	8	$148
Viiv Healthcare Company	1	$125
AMAG Pharmaceuticals, Inc.	1	$124
Baxter Healthcare	2	$94
Hologic Sales And Service, LLC	4	$94
Biogen	4	$86
Organon	4	$67
Medtronic	2	$59
Teleflex LLC	2	$41
Ferring Pharmaceuticals Inc.	1	$30
Samsung HME America, Inc.	1	$30
Therapeuticsmd, Inc.	2	$25
Mylan Pharmaceuticals Inc.	1	$20
Shield Therapeutics Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,773 in reported general payments places this provider in the 85th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Estradiol	13	$794

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Bronx

Tia WelshBronx$24K
Mary PolanNew York$862K
Steven GoldsteinNew York$551K
Veronica LernerNew York$368K
Lisa EngNew York$219K
Theodore GoldmanEast Northport$213K
Miriam CremerBrooklyn$196K
Rachel MaschNew York$187K
Amy PollackNew York$184K
Jian Qun HuangNew York$160K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →